^
Association details:
| Biomarker: | HER-2 amplification + RAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2023
Excerpt:
Rectal cancer....Tucatinib in combination with trastuzumab added as a treatment option for HER2-amplified and RAS and BRAF WT.
